CN107778256B - 一种从邻氨基苯甲酰胺和不饱和醛合成喹唑啉酮的方法 - Google Patents

一种从邻氨基苯甲酰胺和不饱和醛合成喹唑啉酮的方法 Download PDF

Info

Publication number
CN107778256B
CN107778256B CN201610754880.0A CN201610754880A CN107778256B CN 107778256 B CN107778256 B CN 107778256B CN 201610754880 A CN201610754880 A CN 201610754880A CN 107778256 B CN107778256 B CN 107778256B
Authority
CN
China
Prior art keywords
nmr
dmso
1mmol
reaction
anthranilamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201610754880.0A
Other languages
English (en)
Other versions
CN107778256A (zh
Inventor
李峰
赵玮
樊红军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing University of Science and Technology
Original Assignee
Nanjing University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing University of Science and Technology filed Critical Nanjing University of Science and Technology
Priority to CN201610754880.0A priority Critical patent/CN107778256B/zh
Publication of CN107778256A publication Critical patent/CN107778256A/zh
Application granted granted Critical
Publication of CN107778256B publication Critical patent/CN107778256B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明公开了一种从邻氨基苯甲酰胺和不饱和醛合成喹唑啉酮的方法。在反应容器中，加入邻氨基苯甲酰胺、过渡金属催化剂，甲苯和不饱和醛，反应混合物在110‑120℃下反应10‑12小时后，冷却到室温；然后通过分离，得到目标化合物。本发明使用容易获得的邻氨基苯甲酰胺和不饱和醛为起始原料，反应只生成水作为副产物，反应原子经济性高，因此，该反应符合绿色化学的要求，具有广阔的发展前景。

Description

一种从邻氨基苯甲酰胺和不饱和醛合成喹唑啉酮的方法
技术领域
本发明属有机合成化学技术领域，具体涉及一种喹唑啉酮的方法。
背景技术
喹唑啉酮代表一类重要的含氮杂环骨架，它们存在于150多种天然存在的生物碱中，例如Rutaecarppine,Bouchardatine,Luotonin F,Sildenafil and Raltirexed((a)S.B.Mhaske,N.P.Argade,Tetrahedron,2006,62,9787–9826.(b)I.Khan,A.Ibrar,N.Abbas,A.Saeed,Eur.J.Med.Chem.2014,76,193-194 4)。
Figure BDA0001097753830000011
这类化合物也展现出广泛的生物活性，例如抗菌，抗病毒，抗过敏，抗肿瘤等等。(a)Kung,P.P.；Casper,M.D.；Cook,K.L.；Wilson-Lingard,L.；Risen,L.M.；Vickers,T.A.；Ranken,R.；Blyn,L.B.；Wyatt,R.；Cook,P.D.；Ecker,D.J.J.Med.Chem.1999,42,4705-4713.Liverton,N.J.；Armstrong,D.J.；Claremon,D.A.；Remy,D.C.；Baldwin,J.J.；Lynch,R.J.；Zhang,G.；Gould,R.J.Bioorg.Med.Chem.Lett.1998,8,483-487.b)Z.W.Wang,M.X.Wang,X.Yao,Y.Li,J.Tan,L.Z.Wang,W.T.Qiao,Y.Q.Geng,Y.X.Liu and Q.M.Wang,Eur.J.Med.Chem.,2012,53,275-282.c)Laszlo,S.E.；Quagliato,C.S.；Greenlee,W.J.；Patchett,A.A.；Chang,R.S.L.；Lotti,V.J.；Chen,T.B.；Scheck,S.A.；Faust,K.A.；Kivlighn,S.S.；Schorn,T.S.；Zingaro,G.J.；Siegl,P.K.S.J.Med.Chem.1993,36,3207-3210.d)M.M.Aly,Y.A.Mohamed,K.A.El-Bayouki,W.M.Basyouni,S.Y.Abbas,Eur.J.Med.Chem.,2010,45,3365-3373.e)Kobayashi,S.；Ueno,M.；Suzuki,R.；Ishitani,H.Tetrahedron Lett.1999,40,2175-2178.f)Cao,S.L.；Feng,Y.P.；Jiang,Y.Y.；Liu,S.Y.；Ding,G.Y.；Li,R.T.Bioorg.Med.Chem.Lett.2005,15,1915-1917)
传统上，这类化合物是通过邻氨基苯甲酰胺和醛发生缩合反应生成中间体，然后再发生 氧化反应来合成。尽管目前还广泛使用，这种方法要求当量或过量的有毒或者有害氧化剂，如KMnO4,MnO2,CuCl,DDQ,I2,t-BuOOH and PhI(OAc)2。反应也不可避免的生成大量副产物。
Figure BDA0001097753830000021
从可持续化学的角度，发展一个新的方法从更容易获得的原料在更环境友好的条件来合成喹唑啉酮显然是紧迫和很有意义的工作。
发明内容
本发明的目的在于提供一种合成喹唑啉酮的方法。
本发明通过下述技术方案实现：合成喹唑啉酮(式Ⅰ)的方法，
Figure BDA0001097753830000022
其包含邻氨基苯甲酰胺(式Ⅱ)
Figure BDA0001097753830000023
与不饱和醛(式III)
Figure BDA0001097753830000024
发生缩合反应生成含双键的2,3-二氢喹唑啉-4(3H)-酮(式IV)后
Figure BDA0001097753830000031
反应发生脱氢转移加氢反应
反应是在过渡金属催化剂存在下发生，其反应通式为
Figure BDA0001097753830000032
其中，R1选自甲基、甲氧基、卤素、三氟甲基；
R2代表烷基、苯基、甲基苯基、甲氧基苯基、卤代苯基、呋喃基、蒽基；
R3选自氢、烷基；
本发明合成喹唑酮的方法通过下述具体步骤实现：
氮气保护下，在反应容器中，加入邻氨基苯甲酰胺，过渡金属催化剂，溶剂甲苯，不饱和醛；反应混合物在110-120℃下反应10-12小时后，冷却到室温；然后通过分离，得到目标化合物。
其中所述的过渡金属催化剂为金属铱络合物[Cp*IrCl2]2(Cp*＝pentamethylcyclopentadienyl)，过渡金属催化剂的用量为邻氨基苯甲酰胺的1mol％，不饱和醛的摩尔量为邻氨基苯腈摩尔量的1.0-1.5equiv.。
同现有技术相比，本发明从邻氨基苯甲酰胺和不饱和醛作为起始原料，在过渡金属催化剂的参与下发生氢自动转移，得到喹唑啉酮，反应展现出三个显著的优点：1)使用商品化、容易获得的邻氨基苯甲酰胺和不饱和醛为起始原料；2)反应只生成水作为副产物；3)反应原子经济性高；因此，该反应符合绿色化学的要求，具有广阔的发展前景。
具体实施方式
展示一下实例来说明本发明的某些实施例，且不应解释为限制本发明的范围。对本发明 公开的内容可以同时从材料，方法和反应条件上进行许多改进，变化和改变。所有这些改进，变化和改变均确定地落入本发明的精神和范围之内。
实施例1:2-苯乙基喹唑啉-4(3H)-酮
2-phenethylquinazolin-4(3H)-one
Figure BDA0001097753830000041
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，肉桂醛(132mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：90％。
1H NMR(500MHz,DMSO-d6)δ12.26(br s,1H),8.08(d,J＝7.2Hz,1H),7.78(t,J＝6.7Hz,1H),7.62(d,J＝7.6Hz,1H),7.46(t,J＝6.6Hz,1H),7.30-7.26(m,4H),7.21-7.17(m,1H),3.05(t,J＝7.3Hz,2H),2.89(t,J＝7.3Hz,2H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.7,156.5,148.8,140.7,134.3,128.3,126.8,126.0,126.0,125.7,120.8,36.3,32.4.
实施例2:2-(3-甲苯苯乙基)喹唑啉-4(3H)-酮
2-(3-methylphenethyl)quinazolin-4(3H)-one
Figure BDA0001097753830000042
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，间甲基肉桂醛(146mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：88％。
1H NMR(500MHz,DMSO-d6)δ12.24(br s,1H),8.08(d,J＝7.4Hz,1H),7.78(t,J＝7.6Hz,1H),7.62(d,J＝8.1Hz,1H),7.46(t,J＝7.3Hz,1H),7.16(t,J＝7.6Hz,1H),7.10(s,1H),7.05(d,J＝7.5Hz,1H),7.00(d,J＝7.2Hz,1H),3.01(t,J＝8.0Hz,2H),2.87(t,J＝8.0Hz,2H),2.26(s,3H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.8,156.6,148.9,140.6,137.3,134.3,129.0,128.2, 126.8,126.7,126.0,125.7,125.3,120.8,36.3,32.4,21.0.HRMS-EI(70eV)m/z cacld for C17H16N2ONa[M+Na]+287.1160,found 287.1166.
实施例3:2-(2-甲氧基苯乙基)喹唑啉-4(3H)-酮
2-(2-methoxyphenethyl)quinazolin-4(3H)-one
Figure BDA0001097753830000051
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，邻甲氧基肉桂醛(162mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：91％。
1H NMR(500MHz,DMSO-d6)δ12.20(br s,1H),8.09(d,J＝7.7Hz,1H),7.78(t,J＝7.6Hz,1H),7.62(d,J＝8.1Hz,1H),7.46(t,J＝7.4Hz,1H),7.20-7.18(m,2H),6.95(d,J＝8.5Hz,1H),6.86(t,J＝7.3Hz,1H),3.76(s,3H),3.03(t,J＝7.8Hz,2H),2.85(t,J＝7.8Hz,2H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.7,157.1,156.8,148.8,134.2,129.5,128.4,127.5,126.8,125.9,125.6,120.8,120.2,110.6,55.2,34.5,27.0.HRMS-EI(70eV)m/zcacld for C17H15N2O2[M-H]-279.1134,found 279.1140.
实施例4:2-(3-甲氧基苯乙基)喹唑啉-4(3H)-酮
2-(3-methoxyphenethyl)quinazolin-4(3H)-one
Figure BDA0001097753830000052
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，间甲氧基肉桂醛(162mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：86％。
1H NMR(500MHz,DMSO-d6)δ12.24(br s,1H),8.08(d,J＝7.7Hz,1H),7.78(t,J＝7.4Hz, 1H),7.62(d,J＝8.1Hz,1H),7.47(t,J＝7.4Hz,1H),7.19(t,J＝7.8Hz,1H),6.83-6.86(m,2H),6.75(d,J＝7.8Hz,1H),3.71(s,3H),3.02(t,J＝7.8Hz,2H),2.89(t,J＝7.8Hz,2H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.8,159.3,156.6,148.8,142.3,134.3,129.3,126.8,126.0,125.7,120.8,120.5,114.0,111.6,54.8,36.2,32.5.
实施例5:2-(4-氟苯乙基)喹唑啉-4(3H)-酮
2-(4-fluorophenethyl)quinazolin-4(3H)-one
Figure BDA0001097753830000061
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，对氟肉桂醛(150mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：82％。
1H NMR(500MHz,DMSO-d6)δ12.25(br s,1H),8.08(d,J＝7.9Hz,1H),7.78(t,J＝7.6Hz,1H),7.61(d,J＝8.1Hz,1H),7.46(t,J＝7.5Hz,1H),7.32-7.30(m,2H),7.10(t,J＝8.8Hz,2H),3.04(t,J＝8.0Hz,2H),2.88(t,J＝8.0Hz,2H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.7,159.8,156.4,148.8,136.8,134.3,130.1(d,JC-F＝7.7Hz),126.8,126.0,125.7,120.8,115.0(d,JC-F＝21.0Hz),36.4,31.6.HRMS-EI(70eV)m/z cacld for C16H13N2OFNa[M+Na]+291.0910,found291.0917.
实施例6:2-(4-溴苯乙基)喹唑啉-4(3H)-酮
2-(4-bromophenethyl)quinazolin-4(3H)-one
Figure BDA0001097753830000062
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(2.0mL)，对溴肉桂醛(211mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：77％。
1H NMR(500MHz,DMSO-d6)δ12.23(br s,1H),8.08(d,J＝7.8Hz,1H),7.78(t,J＝7.8Hz,1H),7.61(d,J＝8.1Hz,1H),7.48-7.45(m,3H),7.24(d,J＝8.3Hz,2H),3.03(t,J＝7.9Hz,2H),2.88(t,J＝7.9Hz,2H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.7,156.3,148.8,140.2,134.3,131.2,130.6,126.8,126.0,125.7,120.8,119.1,35.9,31.7.HRMS-EI(70eV)m/z cacld for C16H14BrN2O[M+H]-329.0290,found 329.0284.
实施例7:2-(1-苯基-2-丙基)喹唑啉-4(3H)-酮
2-(1-phenylpropan-2-yl)quinazolin-4(3H)-one
Figure BDA0001097753830000071
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，α-甲基肉桂醛(146mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：80％。
1H NMR(500MHz,DMSO-d6)δ12.21(br s,1H),8.07(d,J＝7.6Hz,1H),7.77(t,J＝7.2Hz,1H),7.63(d,J＝8.1Hz,1H),7.46(t,J＝7.4Hz,1H),7.26-7.20(m,4H),7.15(t,J＝7.0Hz,1H),3.15(dd,J＝13.2Hz,J＝7.2Hz,1H),3.05(sext,J＝7.0Hz,1H),2.77(dd,J＝13.2Hz,J＝7.8Hz,1H),1.21(d,J＝6.8Hz,3H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.8,160.4,148.8,139.7,134.3,128.9,128.2,126.9,126.1,126.0,125.6,120.9,40.6,40.2,18.2.HRMS-EI(70eV)m/z cacld for C17H16N2ONa[M+Na]+287.1160,found 287.1165.
实施例8:2-(1-苯基-2-庚基)喹唑啉-4(3H)-酮
2-(1-phenylheptan-2-yl)quinazolin-4(3H)-one
Figure BDA0001097753830000072
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，α-戊基肉桂醛(202mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：84％。
1H NMR(500MHz,DMSO-d6)δ12.12(br s,1H),8.05(d,J＝7.8Hz,1H),7.76(t,J＝7.5Hz,1H),7.62(d,J＝7.9Hz,1H),7.44(t,J＝7.4Hz,1H),7.20(t,J＝7.2Hz,2H),7.15-7.10(m,3H),3.09(dd,J＝12.7Hz,J＝8.7Hz,1H),2.99-2.94(m,1H),2.87(dd,J＝13.0Hz,J＝6.2Hz,1H),1.84-1.78(m,1H),1.59-1.54(m,1H),1.24-1.12(m,6H),0.80-0.73(m,3H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.8,159.8,148.9,139.6,134.6,128.8,128.2,126.9,126.0,125.9,125.7,120.7,46.5,39.3,32.8,31.1,26.3,21.8,13.8.HRMS-EI(70eV)m/zcacld for C21H23N2O[M-H]-319.1810,found 319.1816.
实施例9:2-(1-苯基-2-辛基)喹唑啉-4(3H)-酮
2-(1-phenyloctan-2-yl)quinazolin-4(3H)-one
Figure BDA0001097753830000081
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，α-己基肉桂醛(216mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：88％。
1H NMR(500MHz,DMSO-d6)δ12.13(br s,1H),8.05(d,J＝8.1Hz,1H),7.77(t,J＝7.6Hz,1H),7.62(d,J＝8.1Hz,1H),7.45(t,J＝7.3Hz,1H),7.21(t,J＝7.5Hz,2H),7.16-7.11(m,3H),3.10(dd,J＝13.6Hz,J＝8.5Hz,1H),3.00-2.94(m,1H),2.87(dd,J＝13.4Hz,J＝6.5Hz,1H),1.84-1.78(m,1H),1.60-1.54(m,1H),1.24-1.12(m,8H),0.79(t,J＝6.9Hz,3H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.7,159.7,148.9,139.6,134.2,128.7,128.1,126.9,125.9,125.8,125.6,120.7,46.4,39.2,32.8,30.9,28.4,26.6,21.9,13.7.HRMS-EI(70eV)m/z cacld for C22H25N2O[M-H]-333.1967,found 333.1975.
实施例10:2-(2-(10-蒽基)乙基)喹唑啉-4(3H)-酮
2-(2-(anthracen-10-yl)ethyl)quinazolin-4(3H)-one
Figure BDA0001097753830000091
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(5.0mL)，9-蒽丙烯醛(232mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：81％。
1H NMR(500MHz,DMSO-d6)δ12.46(br s,1H),8.54(s,1H),8.47(d,J＝8.7Hz,2H),8.12(t,J＝8.2Hz,3H),7.82(t,J＝7.4Hz,1H),7.72(d,J＝8.1Hz,1H),7.58(t,J＝7.4Hz,2H),7.55-7.48(m,3H),4.08(t,J＝8.1Hz,2H),3.04(t,J＝8.1Hz,2H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.9,156.6,149.0,134.3,132.8,131.1,129.2,129.0,126.9,126.1,126.0,126.0,125.7,125.1,124.2,120.9,35.9,25.0.HRMS-EI(70eV)m/z cacld for C24H17N2O[M-H]-349.1341,found349.1348.
实施例11:2-(2-(2-呋喃基)乙基)喹唑啉-4(3H)-酮
2-(2-(furan-2-yl)ethyl)quinazolin-4(3H)-one
Figure BDA0001097753830000092
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，2-呋喃丙烯醛(122mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：87％。
1H NMR(500MHz,DMSO-d6)δ12.26(br s,1H),8.08(d,J＝7.6Hz,1H),7.78(t,J＝7.2Hz,1H),7.61(d,J＝8.1Hz,1H),7.52(s,1H),7.46(t,J＝7.5Hz,1H),6.34(s,1H),6.13(d,J＝2.6Hz,1H),3.11(t,J＝7.7Hz,2H),2.93(t,J＝7.7Hz,2H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.7,156.1,154.1,148.8,141.5,134.3,126.8,126.0,125.7,120.9,110.4,105.5,32.8,24.6.
实施例12:2-(1-苯丁基)喹唑啉-4(3H)-酮
2-(1-phenylbutyl)quinazolin-4(3H)-one
Figure BDA0001097753830000101
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，2-苯基-2-戊烯醛(160mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：83％。
1H NMR(500MHz,DMSO-d6)δ12.27(br s,1H),8.06(d,J＝6.1Hz,1H),7.78(t,J＝6.4Hz,1H),7.68(d,J＝5.8Hz,1H),7.47-7.41(m,3H),7.31(t,J＝5.7Hz,2H),7.24-7.19(m,1H),3.96-3.92(m,1H),2.30-7.20(m,1H),1.98-1.84(m,1H),1.31-1.15(m,2H),0.94-0.81(m,3H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.8,158.5,148.8,141.0,134.3,128.4,127.8,127.1,126.9,126.2,125.7,120.8,49.3,35.4,20.2,13.7.HRMS-EI(70eV)m/zcacld for C18H17N2O[M-H]-277.1341,found 277.1347.
实施例13:2-(4-甲基-1-苯戊基)喹唑啉-4(3H)-酮
2-(4-methyl-1-phenylpentyl)quinazolin-4(3H)-one
Figure BDA0001097753830000102
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，5-甲基-2-苯基-2-己烯醛(188mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：89％。
1H NMR(500MHz,DMSO-d6)1H NMR(500MHz,DMSO-d6)δ12.25(br s,1H),8.06(d,J＝7.6Hz,1H),7.78(t,J＝7.2Hz,1H),7.67(d,J＝7.5Hz,1H),7.47-7.43(m,3H),7.31(t,J＝7.2Hz,2H),7.22(t,J＝6.8Hz,1H),3.87(t,J＝7.4Hz,1H),2.30-7.23(m,1H),1.98-1.89(m,1H),1.57-1.50(m,1H),1.17-1.04(m,2H),0.86(t,J＝5.9Hz,6H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.8,158.5,148.8,141.1,134.4,128.4,127.8,127.2,126.9,126.2,125.7,120.8,49.9,36.3,31.1,27.3,22.4.HRMS-EI(70eV)m/z cacld for C20H21N2O[M-H]-305.1654,found 305.1660.
实施例14:2-丙基喹唑啉-4(3H)-酮
2-propylquinazolin-4(3H)-one
Figure BDA0001097753830000111
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，巴豆醛(105mg,1.5mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：84％。
1H NMR(500MHz,DMSO-d6)δ12.15(br s,1H),8.07(d,J＝8.0Hz,1H),7.76(t,J＝7.5Hz,1H),7.59(d,J＝8.2Hz,1H),7.45(t,J＝7.6Hz,1H),2.57(t,J＝7.6Hz,2H),1.74(sext,J＝7.4Hz,2H),0.93(t,J＝7.4Hz,3H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.8,157.3,148.9,134.2,126.8,125.9,125.6,120.8,36.3,20.2,13.4.
实施例15:2-(2-戊基)喹唑啉-4(3H)-酮
2-(pentan-2-yl)quinazolin-4(3H)-one
Figure BDA0001097753830000112
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，2-甲基-2-戊烯醛(98mg,1.0mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：80％。
1H NMR(500MHz,DMSO-d6)δ12.11(br s,1H),8.08(d,J＝7.7Hz,1H),7.77(t,J＝7.5Hz,1H),7.60(d,J＝8.1Hz,1H),7.45(t,J＝7.4Hz,1H),2.76(sext,J＝6.9Hz,1H),1.82-1.74(m,1H),1.54-1.47(m,1H),1.35-1.14(m,5H),0.86(t,J＝7.3Hz,3H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.9,161.1,148.9,134.1,126.9,125.8,125.6,120.8,38.5,36.6,19.9,18.5,13.8.
实施例16:2-(3-庚基)喹唑啉-4(3H)-酮
2-(heptan-3-yl)quinazolin-4(3H)-one
Figure BDA0001097753830000121
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，2-乙基-2-己烯醛(126mg,1.0mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：86％。
1H NMR(500MHz,DMSO-d6)δ12.12(br s,1H),8.08(d,J＝7.7Hz,1H),7.76(t,J＝7.4Hz,1H),7.61(d,J＝8.0Hz,1H),7.45(t,J＝7.4Hz,1H),2.58-2.52(m,1H),1.80-1.71(m,2H),1.64-1.54(m,2H),1.28-1.18(m,3H),1.13-1.07(m,1H),0.82-0.78(m,6H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.9,160.3,149.0,134.2,126.9,125.8,125.6,120.8,46.4,32.6,29.1,26.3,22.1,13.7,11.7.
实施例17:2-环己基喹唑啉-4(3H)-酮
2-cyclohexylquinazolin-4(3H)-one
Figure BDA0001097753830000122
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，3-环己烯甲醛(110mg,1.0mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：89％。
1H NMR(500MHz,DMSO-d6)δ12.06(br s,1H),8.07(d,J＝7.5Hz,1H),7.76(t,J＝6.9Hz,1H),7.59(d,J＝7.9Hz,1H),7.45(t,J＝7.2Hz,1H),2.57(t,J＝11.4Hz,1H),1.90(d,J＝11.4Hz,2H),1.79(d,J＝12.1Hz,2H),1.68(d,J＝10.8Hz,1H),1.62-1.54(m,2H),1.34-1.21(m,3H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.9,160.7,148.9,134.2,126.9,125.9,125.6,120.9,42.8,30.2,25.5,25.3.
实施例18:2-(二环[2.2.1]-2-庚基)喹唑啉-4(3H)-酮
2-(bicyclo[2.2.1]heptan-2-yl)quinazolin-4(3H)-one
Figure BDA0001097753830000131
氮气保护下，将2-氨基苯甲酰胺(136mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，5-降冰片烯-2-甲醛(122mg,1.0mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：87％。
1H NMR(500MHz,DMSO-d6):δ12.13(br s,1H),8.06(d,J＝8.0Hz,1H),7.75(t,J＝7.7Hz,1H),7.60(d,J＝8.0Hz,1H),7.44(t,J＝7.5Hz,1H),2.68(quart,J＝3.5Hz,1H),2.45(d,J＝3.0Hz,1H),2.32-2.29(m,1H),2.25-2.20(m,1H),1.58-1.45(m,4H),1.34(t,J＝10.5Hz,1H),1.25-1.20(m,1H),1.08(d,J＝9.2Hz,1H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.9,169.7,148.6,134.1,127.1,125.9,125.6,120.8,45.5,42.3,35.7,35.3,33.3,29.3,28.4.HRMS-EI(70eV)m/z cacld for C15H15N2O[M-H]-239.1184,found 239.1190.
实施例19:7-甲基-2-苯乙基喹唑啉-4(3H)-酮
7-methyl-2-phenethylquinazolin-4(3H)-one
Figure BDA0001097753830000132
氮气保护下，将2-氨基-4-甲基苯甲酰胺(150mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，肉桂醛(132mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：80％。
1H NMR(500MHz,DMSO-d6)δ12.16(br s,1H),7.96(d,J＝8.0Hz,1H),7.43(s,1H),7.30-7.26(m,5H),7.21-7.17(m,1H),3.04(t,J＝7.8Hz,2H),2.88(t,J＝7.8Hz,2H),2.44(s,3H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.6,156.5,149.0,144.7,140.7,128.3(2C),127.4,126.5,126.0,125.5,118.4,36.2,32.4,21.3.HRMS-EI(70eV)m/z cacld forC17H16N2ONa[M+Na]+287.1160,found 287.1168.
实施例20:6-甲氧基-2-苯乙基喹唑啉-4(3H)-酮
6-methoxy-2-phenethylquinazolin-4(3H)-one
Figure BDA0001097753830000141
氮气保护下，将2-氨基-5-甲氧基苯甲酰胺(166mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(5.0mL)，肉桂醛(132mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：77％。
1H NMR(500MHz,DMSO-d6):δ12.22(br s,1H),7.57(d,J＝8.8Hz,1H),7.47(s,1H),7.38(d,J＝8.7Hz,1H),7.31-7.24(m,4H),7.21-7.17(m,1H),3.85(s,3H),3.03(t,J＝7.8Hz,2H),2.87(t,J＝7.8Hz,2H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.6,157.2,154.1,143.3,140.8,128.5,128.3(2C),126.0,123.7,121.5,105.7,55.5,36.1,32.5.HRMS-EI(70eV)m/z cacld for C17H17N2O2[M+H]+281.1290,found 281.1298.
实施例21:6-氯-2-苯乙基喹唑啉-4(3H)-酮
6-chloro-2-phenethylquinazolin-4(3H)-one
Figure BDA0001097753830000142
氮气保护下，将2-氨基-5-氯苯甲酰胺(171mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，肉桂醛(132mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：84％。
1H NMR(500MHz,DMSO-d6):δ12.44(br s,1H),8.01(d,J＝2.2Hz,1H),7.80(dd,J＝8.7Hz,J＝2.4Hz,1H),7.64(d,J＝8.7Hz,1H),7.30-7.25(m,4H),7.21-7.17(m,1H),3.04(t,J＝8.0Hz,2H),2.89(t,J＝8.0Hz,2H)；13C{1H}NMR(125MHz,DMSO-d6)δ160.7,157.2,147.5,140.6,134.3,130.2,129.0,128.3,128.3,126.1,124.7,122.1,36.3,32.3.
实施例22:7-氯-2-苯乙基喹唑啉-4(3H)-酮
7-chloro-2-phenethylquinazolin-4(3H)-one
Figure BDA0001097753830000151
氮气保护下，将2-氨基-4-氯苯甲酰胺(171mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，肉桂醛(132mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：86％。
1H NMR(500MHz,DMSO-d6)δ12.39(br s,1H),8.07(d,J＝6.9Hz,1H),7.67(s,1H),7.50(d,J＝6.1Hz,1H),7.33-7.23(m,4H),7.22-7.15(m,1H),3.04(s,2H),2.90(s,2H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.1,158.3,149.9,140.6,138.9,128.3,128.3,127.8,126.3,126.1,125.9,119.6,36.3,32.3.
实施例23:6-溴-2-苯乙基喹唑啉-4(3H)-酮
6-bromo-2-phenethylquinazolin-4(3H)-one
Figure BDA0001097753830000152
氮气保护下，将2-氨基-5-溴苯甲酰胺(215mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，肉桂醛(132mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：83％。
1H NMR(500MHz,DMSO-d6)δ12.45(br s,1H),8.16(d,J＝2.1Hz,1H),7.92(dd,J＝8.6Hz,J＝2.1Hz,1H),7.58(d,J＝8.6Hz,1H),7.31-7.26(m,4H),7.19(t,J＝6.5Hz,1H),3.05(t,J＝8.0Hz,2H),2.89(t,J＝8.0Hz,2H)；13C{1H}NMR(125MHz,DMSO-d6)δ160.6,157.4,147.7,140.6,137.1,129.2,128.3,128.3,127.8,126.1,122.4,118.3,36.3,32.3.
实施例24:7-三氟甲基-2-苯乙基喹唑啉-4(3H)-酮
7-trifluoromethyl-2-phenethylquinazolin-4(3H)-one
Figure BDA0001097753830000161
氮气保护下，将2-氨基-4-三氟甲基苯甲酰胺(204mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，肉桂醛(132mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：86％。
1H NMR(500MHz,DMSO-d6)δ12.58(br s,1H),8.28(d,J＝8.2Hz,1H),7.94(s,1H),7.77(d,J＝8.2Hz,1H),7.31-7.27(m,4H),7.22-7.18(m,1H),3.07(t,J＝8.0Hz,2H),2.93(t,J＝8.0Hz,2H)；13C{1H}NMR(125MHz,DMSO-d6)δ161.0,158.5,148.8,140.5,134.0(q,JC-F＝32.1Hz),128.3,128.3,127.5,126.1,123.8,123.6,123.5(q,JC-F＝272.0Hz),121.7,36.3,32.3.HRMS-EI(70eV)m/z cacld for C17H14N2OF3[M+H]+319.1058,found 319.1067.
实施例25:3-苄基-2-苯乙基喹唑啉-4(3H)-酮
3-benzyl-2-phenethylquinazolin-4(3H)-one
Figure BDA0001097753830000162
氮气保护下，将2-氨基-N-苄基苯甲酰胺(226mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，肉桂醛(132mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：84％。
1H NMR(500MHz,DMSO-d6)δ8.32(d,J＝8.0Hz,1H),7.76(t,J＝7.6Hz,1H),7.71(d,J＝8.0Hz,1H),7.48(t,J＝7.6Hz,1H),7.32-7.24(m,5H),7.20(t,J＝7.3Hz,1H),7.14(d,J＝7.4Hz,4H),5.35(s,2H),3.11(t,J＝8.0Hz,2H),3.04(t,J＝8.0Hz,2H)；13C{1H}NMR(125MHz,CDCl3)δ162.5,156.3,147.3,140.5,136.1,134.3,128.9,128.5,128.4,127.6,127.1,127.0,126.6,126.4,126.3,120.4,46.2,36.6,33.1.HRMS-EI(70eV)m/z cacld forC23H21N2O[M+H]+341.1654,found 341.1649.
实施例26:3-丁基-2-苯乙基喹唑啉-4(3H)-酮
3-butyl-2-phenethylquinazolin-4(3H)-one
Figure BDA0001097753830000171
氮气保护下，将2-氨基-N-丁基苯甲酰胺(192mg,1mmol)，[Cp*IrCl2]2(8mg,0.01mmol,1mol％)，甲苯(1.0mL)，肉桂醛(132mg,1mmol)依次加到25mL Schlenk反应瓶中。混合物在120℃下反应12小时后，冷却到室温。真空减压除去溶剂，然后通过柱层析(展开剂：乙酸乙酯/石油醚)得到纯净的目标化合物，产率：82％。
1H NMR(500MHz,DMSO-d6)δ8.26(d,J＝7.9Hz,1H),7.73(t,J＝7.4Hz,1H),7.67(d,J＝8.1Hz,1H),7.44(t,J＝7.4Hz,1H),7.35-7.23(m,5H),4.04(t,J＝7.8Hz,2H),3.22(t,J＝7.9Hz,2H),3.12(t,J＝7.9Hz,2H),1.68-1.63(m,2H),1.42(sext,J＝7.5Hz,2H),0.96(t,J＝7.4Hz,3H)；13C{1H}NMR(125MHz,CDCl3)δ162.2,155.8,147.2,140.7,134.0,128.7,128.4,126.8,126.7,126.4,126.4,120.5,43.5,36.7,33.4,31.0,20.3,13.7.HRMS-EI(70eV)m/z cacld for C20H23N2O[M+H]+307.1810,found 307.1805. 。

Claims (3)

1.一种合成如式I所示的喹唑啉酮衍生物的方法，其特征在于，
Figure FDA0002446186320000011
是通过邻氨基苯甲酰胺Ⅱ
Figure FDA0002446186320000012
与不饱和醛III
Figure FDA0002446186320000013
发生缩合反应，生成含双键的2,3-二氢喹唑啉-4(3H)-酮IV后
Figure FDA0002446186320000014
再发生脱氢转移加氢反应，
其中，R1选自甲基、甲氧基、卤素、三氟甲基；
R2代表烷基、苯基、甲基苯基、甲氧基苯基、卤代苯基、呋喃基、蒽基；
R3选自氢、烷基；
包括如下步骤：氮气保护下，在反应容器中，加入邻氨基苯甲酰胺，过渡金属催化剂，溶剂甲苯，不饱和醛；反应混合物在110-120℃下反应，反应结束后冷却到室温；然后通过分离，得到目标化合物；
其中，过渡金属催化剂为金属铱络合物[Cp*IrCl2]2，Cp*＝pentamethylcyclopentadienyl。
2.根据权利要求1所述的方法，其特征是，过渡金属催化剂用量相对于邻氨基苯酰胺为1mol％，不饱和醛摩尔量相对于邻氨基苯酰胺摩尔量为1.0-1.5equiv.。
3.根据权利要求1所述的方法，其特征是，反应时间为10-12小时。
CN201610754880.0A 2016-08-29 2016-08-29 一种从邻氨基苯甲酰胺和不饱和醛合成喹唑啉酮的方法 Expired - Fee Related CN107778256B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610754880.0A CN107778256B (zh) 2016-08-29 2016-08-29 一种从邻氨基苯甲酰胺和不饱和醛合成喹唑啉酮的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610754880.0A CN107778256B (zh) 2016-08-29 2016-08-29 一种从邻氨基苯甲酰胺和不饱和醛合成喹唑啉酮的方法

Publications (2)

Publication Number Publication Date
CN107778256A CN107778256A (zh) 2018-03-09
CN107778256B true CN107778256B (zh) 2020-06-19

Family

ID=61441509

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610754880.0A Expired - Fee Related CN107778256B (zh) 2016-08-29 2016-08-29 一种从邻氨基苯甲酰胺和不饱和醛合成喹唑啉酮的方法

Country Status (1)

Country Link
CN (1) CN107778256B (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106518789A (zh) * 2015-09-15 2017-03-22 南京理工大学 一种合成喹唑啉酮衍生物的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106518789A (zh) * 2015-09-15 2017-03-22 南京理工大学 一种合成喹唑啉酮衍生物的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Benign and Efficient Synthesis of 2-Substituted 4(3H)-Quinazolinones Mediated by Iron(III) Chloride Hexahydrate in Refluxing Water;Guan-Wu Wang et al.;《Bull.Chem.Soc.Jpn.》;20060905;第79卷(第9期);1426-1430 *
Efficient syntheses of 2,3-disubstituted natural quinazolinones via iridium catalysis;Jie Fang et al.;《Org.Biomol.Chem.》;20120125;第10卷;2389-2391 *
One-Pot Synthesis of Quinazolinones via Iridium-Catalyzed Hydrogen Transfers;Jianguang Zhou et al.;《J.Org.Chem.》;20110818;第76卷;7730-7736 *

Also Published As

Publication number Publication date
CN107778256A (zh) 2018-03-09

Similar Documents

Publication Publication Date Title
MX2010014224A (es) Un proceso para la preparacion del promotor de apoptosis abt-263.
JP6696986B2 (ja) ジアリールチオヒダントイン化合物の調製方法
Khan et al. Synthesis of functionalized dihydro-2-oxypyrroles and tetrahydropyridines using 2, 6-pyridinedicarboxylic acid as an efficient and mild organocatalyst
JP6851149B2 (ja) ピペリジン化合物の製造方法
CN109384731B (zh) 一种由烯醇制备喹唑啉酮的方法
Samzadeh‐Kermani Copper catalyzed synthesis of thiomorpholine derivatives: a new entry of multicomponent reaction between terminal Alkynes, isothiocyanates, and aziridines
CN107778256B (zh) 一种从邻氨基苯甲酰胺和不饱和醛合成喹唑啉酮的方法
PH12015501717B1 (en) Process for producing pyridazinone compound and production intermediates thereof
JP6028606B2 (ja) アミン化合物の製造方法
CN113754605B (zh) 一种含氮配体及其制备方法和应用
WO2008135386A1 (fr) Ligands chiraux de type carbenes n-heterocycliques pour la catalyse asymetrique
CN107915653A (zh) 催化酯和胺进行反应制备酰胺的方法
CN110028448B (zh) 一种3-羟基-2,3-二氢异喹啉-1,4-二酮化合物的制备方法
CN110845423A (zh) 一种1,2-取代苯并咪唑类化合物的制备方法
CN108218864B (zh) 一种四氢-β-咔啉杂环化合物的绿色合成方法
CN112661668A (zh) 一种n-取代酰胺类化合物及其制备方法
JP2018521037A (ja) １−シクロプロピル−ナフタレンを製造するためのプロセス
CN109422748B (zh) 合成tnni3k抑制剂的方法
CN107400084B (zh) 一种合成喹啉衍生物的方法
WO2019228873A1 (en) Synthesis of a racemic mixture of pantolactone
JPH0240365A (ja) Ｎ‐ヒドロキシピラゾールの製法
JP2015528813A (ja) 特定の４−ヒドロキシ−２−オキソ−２，５−ジヒドロフラン−３−カルボン酸エステル類のアルカリ金属塩の多段階製造方法
JP3682517B2 (ja) イミンおよびエナミンの製造方法
CN106632340B (zh) 一种合成替诺福韦中间体的方法
JP3272340B2 (ja) １−［（シクロペント−３−エン−１−イル）メチル］−５−エチル−６−（３，５−ジメチルベンゾイル）−２，４−ピリミジンジオンの製造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Li Feng

Inventor after: Zhao Wei

Inventor after: Fan Hongjun

Inventor before: Zhao Wei

Inventor before: Fan Hongjun

Inventor before: Li Feng

CB03 Change of inventor or designer information
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200619